What question did this study set out to answer?

To analyze trends and prevalence of KRAS mutation testing in non-squamous non-small cell lung cancer patients in Queensland from 2014 to 2023.

April 1, 2026Open Access

Ver artículo completo

Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023

NNNavin NiranjanGriffith University TGTracey GuanGriffith University NNNitin NiranjanMetro South Health

Puntos clave

To analyze trends and prevalence of KRAS mutation testing in non-squamous non-small cell lung cancer patients in Queensland from 2014 to 2023.
Conducted a longitudinal analysis of KRAS mutation testing rates
Collected data from patients diagnosed with metastatic non-squamous non-small cell lung cancer
Compared findings with existing literature on KRAS mutations
Significant improvement in KRAS mutation testing rates over time
Characteristics of KRAS mutation-positive patients aligned with published literature

Resumen

This study is the largest longitudinal analysis of KRASM testing conducted in Australia, with significant improvement in testing rates seen over the time period. Rates of KRASM and characteristics of Australian KRAS mt patients correspond with published literature.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023

Puntos clave

Resumen

Cite This Study

Also Consider

Also Consider